The Price Of Revance Therapeutics Inc. (RVNC) Has Climbed $50.68 Past Week

KOSK Stock
KOSK Stock

The stock of Revance Therapeutics Inc. (NASDAQ:RVNC) decreased by -$0.38 on Monday to finish at $28.09, down -1.33 percent. The last five days have seen an average of 3,875,920 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $11.77. The average number of shares traded over the last 20 days was 1,547,800, while the average volume over the last 50 days totaled 982,276.

RVNC stock appreciated 31.02% since last month. On 08/29/22, the company’s shares reached a one-month low of $19.15. The stock touched a high of $30.00 on 09/09/22, after rallying from a low of $11.27 in 52 weeks. The price of RVNC stock has risen by 72.12% or $11.77 this year, reaching a new high 13 times. Still, the stock price is down -6.37% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

There have been 274 days since Revance Therapeutics Inc. (RVNC) last reported insider trading activity on Dec 13. On Dec 13, Director Russell Angus C. acquired 6,400 shares at $15.74 each. This transaction resulted in the insider spending $100,741. On Dec 03, Rankin Aubrey added 30,000 shares at a price of US$14.43. After the transaction, the insider now owns 95,463 shares. CEO Foley Mark J had earlier bought 40,000 shares on Nov 29 for $12.90 a share. The transaction was completed for $515,924.

Financial Health

For the three months ended June 29, Revance Therapeutics Inc.’s quick ratio was 3.20, while its current ratio was 3.40, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 68.60% percent. Based on annual data, it had gross profit of $54.39 million and revenue of $77.8 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RVNC’s return on assets (ROA) during the last 12 months has been -45.50%. There was a -78.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -497.80%.

Earnings Surprise

According to Revance Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29, it had $378.38 million in total debt versus $164.4 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $28.37 million, while revenues rose by 33.73% to $25.26 million. It was predicted that Revance Therapeutics Inc.’s quarterly earnings would be -$0.88, but it ended up being -$0.86, beating the consensus by -2.30%. EBITDA was -$50.83 million for the quarter. At the end of Revance Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 564.51 million, while its total debt was $437.69 million. Equity owned by shareholders amounts to $73.11 million.

Technical Picture

Here’s a quick look at Revance Therapeutics Inc.’s (RVNC) price momentum from a technical perspective. As of 12 September, the RSI 9-day stood at 78.10%, suggesting the stock is Overbought, with a 113.26% historical volatility rate.

The stochastic %K and %D were 91.19% and 75.77% respectively, while the average true range (ATR) was 1.82. Based on the 14-day stochastic reading of 86.29%, the RSI (14) reading is 74.61%. On the 9-day MACD Oscillator, the stock is at 4.47, and the 14-day reading is at 5.31.

Analyst Ratings

Revance Therapeutics Inc. (NASDAQ: RVNC) was downgraded by Wells Fargo to a an Equal weight rating in its latest research report. The stock was previously rated as a an Overweight. Analysts have assigned Revance Therapeutics Inc. (RVNC) an Buy rating. RVNC is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 8 others recommend it as a buy.

What is RVNC’s price target for the next 12 months?

The current consensus forecast for the stock is between $24.00 and $65.00, with a median target price of $30.50. In analyzing these forecasts, the average price target given by analysts for Revance Therapeutics Inc. (RVNC) is $33.80.


Please enter your comment!
Please enter your name here